Alliance Pharma PLC Appointment of NED and SID (4957O)
February 01 2023 - 1:00AM
UK Regulatory
TIDMAPH
RNS Number : 4957O
Alliance Pharma PLC
01 February 2023
For immediate release 1 February 2023
ALLIANCE PHARMA
("Alliance", "Company" or the "Group")
Appointment of Non-Executive Director and Senior Independent
Director
Alliance Pharma plc (AIM: APH), the international healthcare
group, is pleased to announce the appointment of Martin Sutherland
as a new independent Non-Executive Director and Richard Jones, a
Non-Executive Director since 2019, as Senior Independent Director
to strengthen the Board and support the delivery of the Company's
growth strategy.
Martin, who will join the Board with immediate effect, is a
senior executive with over 30 years' experience in global
businesses. He is currently a NED at FTSE listed Forterra plc and
Reliance acsn ltd. Forterra is a leading UK manufacturer of
essential clay and concrete building products. Martin joined the
Board of Forterra in 2017 and sits on the Nomination, Remuneration,
Audit, and Risk & Sustainability committees. Reliance acsn ltd
is a privately held specialist cyber security business, a company
which he joined in 2020 as CEO and helped to drive a doubling of
revenues in two years. Martin stepped down as CEO to become NED in
January 2023.
Martin was CEO of De La Rue plc between 2014 and 2019 and
previously held various roles at Detica plc, becoming Managing
Director in 2008 on its acquisition by BAE Systems plc. Martin has
a proven track record of delivering growth through new product
innovation, market diversification and international expansion. We
believe that Martin's experience will bring a new perspective to
complement the strong consumer healthcare knowledge already present
on the Board.
Following its annual review, the Board has decided to appoint
Richard Jones, current NED and Chair of Audit & Risk Committee,
as Senior Independent Director with immediate effect. Richard is
CFO of Medica Group plc, the UK's leading teleradiology provider,
and has been on the Alliance Board since 1 January 2019.
David Cook, Chair of Alliance, said :
"I am delighted to welcome Martin Sutherland to the Board and
look forward to his contribution to support the delivery of our
growth strategy. Martin will bring significant additional expertise
from his experience as a company director and in senior executive
leadership roles. The Board will also benefit from his 30 years'
experience in managing global businesses and delivering growth.
"I am also pleased to appoint Richard Jones as our first Senior
Independent Director. Richard will help support and expand our
stakeholder engagement programme, building on his extensive
experience in capital markets and leveraging his strong networks
with shareholders."
The following information is disclosed pursuant to Schedule Two,
paragraph (g), of the AIM Rules for Companies.
Mr Martin Conrad Sutherland, aged 54, has been a director of the
following companies during the five years preceding the date of
this announcement:
Current directorships Directorships in the past five
Forterra plc years:
Reliance acsn Limited De La Rue plc
19 Bennerley Road Limited
The International Currency Association
Limited
Mr Sutherland does not hold any ordinary shares of 1 pence each
in the Company.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Cora McCallum, Head of Investor Relations
& Corporate Communications + 44 (0)1249 705168
ir@allianceph.com
+ 44 (0)20 7466
Buchanan 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
+ 44 (0)20 7260
Numis Securities Limited 1000
Nominated Adviser: Freddie Barnfield / Duncan
Monteith
Corporate Broking: James Black
+ 44 (0)20 7597
Investec Bank plc 5970
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group. Our purpose is to improve the lives of consumers and
patients through making available a range of clinically valuable
healthcare products.
Our core focus is on the marketing of Consumer Healthcare
brands, complemented by a smaller Prescription Medicines business.
In total, we hold marketing rights to around 80 brands, with
revenues generated from a mix of direct, distributor and e-commerce
sales.
Headquartered in the UK, the Group employs around 250 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics
operations, we remain asset-light and focused on maximising the
value of our brands.
For more information on Alliance, please visit our website :
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADBGDBBGXDGXB
(END) Dow Jones Newswires
February 01, 2023 02:00 ET (07:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024